FDA分析认为Moderna研发的新冠疫苗有效且安全，计划授权紧急使用

食品和药物管理局周二上午发布了一份来自制药商Moderna的COVID-19疫苗的详细分析报告，支持授权该公司的疫苗紧急使用。接下来专家组将召开会议，就是否授予该疫苗紧急授权使用做出讨论，并向该机构提供建议。

注射Moderna疫苗的患者虽然较小几率出现严重反应，但是副作用却是常见的，大多数志愿者注射后出现了局部疼痛、疲劳和头痛等症状。

研究还发现，疫苗在老年人中效果较差，65岁及以上的人有效性为86%；对于18岁至65岁以下的人，有效性则为96%。

The Food and Drug Administration released a detailed analysis Tuesday morning of the COVID-19 vaccine from drugmaker Moderna that supports the authorization of the company's vaccine for emergency use. The FDA's briefing document along with one from Moderna were posted two days before a group of experts will convene to advise the agency on whether to grant the vaccine emergency authorization for use, or EUA, during the pandemic.

Serious reactions were rare. Side effects are common, however, with a majority of study volunteers experiencing pain at the site of injection, fatigue and headaches.

The vaccine is less effective in older people, the FDA analysis finds. For people ages 18 to less than 65, the effectiveness is 96%, compared with 86% for people 65 and older.  source

指尖新闻：高信噪比，一目了然

新冠疫情追踪